Yuhan Liu

Yuhan Liu

Auto-generated profile, based on publicly available information

Yuhan Liu

Department of Urology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Cancer
Verified
Journal Article
Open access
MDMengting Ding
Mengting Ding
YLYuhan Liu
Yuhan Liu
XLXinhui Liao
Xinhui Liao
HZHengji Zhan
Hengji Zhan
YLYuchen Liu
Yuchen Liu
WHWeiRen Huang
WeiRen Huang
Enhancers are cis-acting elements that have the ability to increase the expression of target genes. Recent studies have shown that enhancers can act as transcriptional units for the production of enhancer RNAs (eRNAs), which are hallmarks of activity enhancers and are involved in the regulation of gene transcription. The in-depth study of eRNAs is of great significance for us to better understand enhancer function and transcriptional regulation in various diseases. Therefore, eRNAs may be a potential therapeutic target for diseases. Here, we review the current knowledge of the characteristics of eRNAs, the molecular mechanisms of eRNAs action, as well as diseases related to dysregulation of eRNAs.

18 May 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YDYing Dong
Ying Dong
CXChaojie Xu
Chaojie Xu
GSGanglin Su
Ganglin Su
Yanfeng LiYanfeng Li
Yanfeng Li
BYBing Yan
Bing Yan
HMHongbing Mei
Hongbing Mei
Background: Anoikis is a programmed cell death process that was proven to be associated with cancer. Uroepithelial carcinoma of the bladder (BLCA) is a malignant disease of the urinary tract and has a strong metastatic potential. To determine whether anoikis-associated genes can predict the prognosis of BLCA accurately, we evaluated the prognostic value of anoikis-associated genes in BLCA and constructed the best model to predict prognosis.Method: The BLCA transcriptome data were downloaded from TCGA and GEO databases, and genes with differential expression were selected and then clustered using non-negative matrix factorization (NMF). The genes with the most correlation with anoikis were screened and identified using univariate Cox regression, lasso regression, and multivariate Cox regression. The GEO dataset was used for external validation. Nomograms were created based on risk characteristics in combination with clinical variants and the performance of the model was validated with receiver operating characteristic (ROC) curves. The immunotherapeutic significance of this risk score was assessed using the immune phenomenon score (IPS). IC50 values of predictive chemotherapeutic agents were calculated. Finally, we used RT-qPCR to determine the mRNA expression of four genes, CALR, FASN, CASP6, and RAD9A.Result: We screened 406 tumor samples and 19 normal tissue samples from the TCGA database. Based on anoikis-associated genes, we classified patients into two subtypes (C1 and C2) using NMF method. Subsequently, nine core genes were screened by multiple methods after analysis, which were used to construct risk profiles. The design of nomograms based on risk profiles and clinical variables, ROC, and calibration curves confirmed that the model could well have the ability to predict the survival of BLCA patients at 1, 3, and 5 years. By predicting the IC50 values of chemotherapeutic drugs, it was learned that the high-risk group (HRG) was more susceptible to paclitaxel, gemcitabine, and cisplatin, and the low-risk group (LRG) was more susceptible to veriparib and afatinib.Conclusion: In summary, the risk score of anoikis-associated genes can be applied as a predictor to predict the prognosis of BLCA in clinical practice.

1 March 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
YLYuhan Liu
Yuhan Liu
AHAnbang He
Anbang He
BLBaoer Liu
Baoer Liu
YZYucheng Zhong
Yucheng Zhong
XLXinhui Liao
Xinhui Liao
HMHongbing Mei
Hongbing Mei
Several epidemiological studies have reported that polymorphisms in microRNA-196a2 (miR-196a2) were associated with various cancers. However, the results remained unverified and were inconsistent in different cancers. Therefore, we carried out an updated meta-analysis to elaborate the effects of rs11614913 polymorphism on cancer susceptibility. A total of 84 articles with 35,802 cases and 41,541 controls were included to evaluate the association between the miR-196a2 rs11614913 and cancer risk by pooled odds ratios (ORs) and 95% confidence intervals (CIs). The results showed that miR-196a2 rs11614913 polymorphism is associated with cancer susceptibility, especially in lung cancer (homozygote comparison, OR =0.840, 95% CI =0.734–0.961; recessive model, OR =0.858, 95% CI =0.771–0.955), hepatocellular carcinoma (allelic contrast, OR =0.894, 95% CI =0.800–0.998; homozygote comparison, OR =0.900, 95% CI =0.813–0.997; recessive model, OR =0.800, 95% CI =0.678–0.944), and head and neck cancer (allelic contrast, OR =1.076, 95% CI =1.006–1.152; homozygote comparison, OR =1.214, 95% CI =1.043–1.413). In addition, significant association was found among Asian populations (allele model, OR =0.847, 95% CI =0.899–0.997, P=0.038; homozygote model, OR =0.878, 95% CI =0.788–0.977, P=0.017; recessive model, OR =0.895, 95% CI =0.824–0.972, P=0.008) but not in Caucasians. The updated meta-analysis confirmed the previous results that miR-196a2 rs11614913 polymorphism may serve as a risk factor for patients with cancers.

19 March 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YLYuhan Liu
Yuhan Liu
AHAnbang He
Anbang He
BLBaoer Liu
Baoer Liu
ZHZhengxian Huang
Zhengxian Huang
HMHongbing Mei
Hongbing Mei
Long noncoding RNAs (lncRNAs) have been reported to serve as diagnostic and prognostic biomarkers of cancers, which play vital roles in tumorigenesis and tumor progression. Several studies have been performed to explore diagnostic value of lncRNA H19 in cancer detection and diagnosis. However, there are still inconsistent results in diagnostic accuracy and reliability in individual studies. Therefore, the present study was performed to summarize the overall diagnostic performance of lncRNA H19 in cancer detection and diagnosis. A total of eight studies with 770 cases and 815 controls were included in this pooled analysis. The pooled diagnostic results were as follows: sensitivity, 0.69 (95%CI=0.62-0.76), specificity, 0.79 (95% CI=0.70-0.86), positive likelihood ratio (PLR), 3.31 (95%CI=2.29-4.78), negative likelihood (NLR), 0.39 (95%CI=0.31-0.49), diagnostic odds ratio (DOR), 8.53 (95%CI=4.99-14.60), and area under the curve (AUC), 0.79 (95%CI=0.76-0.83). Deeks’ funnel plot asymmetry test (P=0.13) suggested no potential publication bias. Our results indicated that lncRNA H19 had a relatively moderate accuracy in cancer detection and diagnosis. Further comprehensive prospective studies with large sample sizes are urgently required to validate our findings.

8 May 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
TYTao Yin
Tao Yin
SMShuanzhu Mou
Shuanzhu Mou
HZHaiyu Zhang
Haiyu Zhang
YDYing Dong
Ying Dong
BYBing Yan
Bing Yan
HMHongbing Mei
Hongbing Mei
Introduction: As proteins that promote immune cell differentiation, chemokines have attracted great interest regarding their role in anti-tumor immune responses within the cancer environment. However, the exact role of CXCL10, a chemokine, in bladder cancer (BLCA) is still not fully elucidated. Method: In the present study, we employed bioinformatics approaches to examine the expression pattern, prognostic value, and immune infiltration of CXCL10 in BLCA. Furthermore, we focused on examining the impact of CXCL10 on immune therapy in BLCA. Additionally, we validated the expression of CXCL10 in various BLCA cell lines using PCR techniques. Results: We observed an upregulation of CXCL10 in BLCA tissues as well as in different cell lines. Additionally, upregulation of CXCL10 indicates a better prognosis for BLCA patients. ESTIMATE and CIBERSORT algorithms suggest that CXCL10 is closely associated with the immune microenvironment of BLCA. Through multiple immune therapy cohorts, we also identified that CXCL10 has shown promising predictive value for assessing the efficacy of immune therapy in in BLCA. Conclusion: Our study indicates that CXCL10 has the potential to serve as a favorable prognostic factor and is strongly associated with immune infiltration in BLCA. Graphical

18 December 2018 in Biomarkers in Medicine
Verified
Journal Article
Closed access
HMHongbing Mei
Hongbing Mei
YLYuhan Liu
Yuhan Liu
QZQun Zhou
Qun Zhou
KHKun Hu
Kun Hu
YLYuchen Liu
Yuchen Liu
Aim: it has been reported that metastasis-associated lung adenocarcinoma transcript 1 is abnormally expressed in various cancers. Methods: eligible studies fulfilling the search criteria were selected from the online databases. Statistical analysis was performed based on the platforms of STATA 14.0. Results: 12 studies were included in this study comprising 741 cases and 794 controls. The pooled results were shown as follows: sensitivity, 0.74 (95% CI: 0.64–0.82), specificity, 0.83 (95% CI: 0.75–0.88), positive likelihood ratio (PLR), 4.2 (95% CI: 3.00–5.90), negative likelihood, 0.32 (95% CI: 0.23–0.43), diagnostic odds ratio, 13 (95%CI: 8.00–21.00) and area under the curve, 0.85 (95%CI: 0.82–0.88). Deeks’ funnel plot asymmetry test (p = 0.70) suggested no potential publication bias. Conclusion: long noncoding RNA Metastasis-associated lung adenocarcinoma transcript 1 might be a usable biomarker for cancer diagnosis and detection.